Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350078 | 1.00 | CTSK (0.58) | CTSKHSD11B1JAK2JAK1GPR119 | |
| SCHEMBL2348338 | 1.00 | CTSK (0.58) | CTSKHSD11B1JAK2JAK1GPR119 | |
| SCHEMBL2348333 | 1.00 | CTSK (0.58) | CTSKHSD11B1JAK2JAK1GPR119 | |
| SCHEMBL15293402 | 0.92 | CTSK (0.49) | CTSKHSD11B1JAK2JAK1GPR119 | |
| SCHEMBL3218733 | 0.92 | CTSK (0.56) | CTSKHSD11B1JAK2JAK1GPR119 | |
| SCHEMBL376621 | 0.92 | CTSK (0.56) | CTSKHSD11B1JAK2JAK1GPR119 | |
| SCHEMBL3218754 | 0.92 | CTSK (0.56) | CTSKHSD11B1JAK2JAK1GPR119 | |
| SCHEMBL3218744 | 0.92 | CTSK (0.56) | CTSKHSD11B1JAK2JAK1GPR119 | |
| SCHEMBL2448494 | 0.92 | CTSK (0.56) | CTSKHSD11B1JAK2JAK1GPR119 | |
| SCHEMBL28791320 | 0.92 | CTSK (0.49) | CTSKHSD11B1JAK2JAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116888-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | NOVARTIS AG (CH) | 2026-04-30 | — | — | US | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4558493-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119894880-A | Quinazoline compounds and methods of use | 依安彼克医疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025059429-A1 | MODULATORS OF BCL6 FOR USE IN A METHOD OF TREATING A CANCER OR AN AUTOIMMUNE DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-119604493-A | Heterocyclic compounds as BCL6 modulators useful as ligand-directed degradants | 细胞基因公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20150119405-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-30 | — | — | US | disclosed |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-1699797-B1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | CTSK 1576/4885HSD11B1 2427/4885JAK2 7/4885 |
| US-20260116888-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK4, CCNC, CDK6 | CTSK 3026/4885HSD11B1 1070/4885JAK2 330/4885 |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | CTSK 597/4885HSD11B1 2517/4885JAK2 2158/4885 |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | PEPD, TFPI, F2 | CTSK 289/4885HSD11B1 2629/4885JAK2 1731/4885 |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | CTSK 1512/4885HSD11B1 2784/4885JAK2 96/4885 |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | BCL6, BCL6B, BCL3 | CTSK 1480/4885HSD11B1 1712/4885JAK2 1051/4885 |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | CTSK 1480/4885HSD11B1 1712/4885JAK2 1051/4885 |
| US-20150119405-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | CTSK 1850/4885HSD11B1 3900/4885JAK2 126/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | CTSK 1576/4885HSD11B1 2427/4885JAK2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.